Literature DB >> 7617808

Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats.

J Turchi1, L A Holley, M Sarter.   

Abstract

The effects of nicotinic receptor ligands on performance in a task measuring sustained attention, or vigilance, were tested. This task required the animals to discriminate between signal and non-signal events. The sequence of signal (central panel light illumination for 500, 50 or 25 ms) and non-signal presentations was randomized over three blocks of 54 trials each (27 signal trials, 9 per length, and 27 non-signal trials). A left lever press following a signal was counted as a hit, and a right lever press following a non-signal event was counted as a correct rejection. Hits and correct rejections were rewarded, whereas misses and false alarms (defined as incorrect right and left lever presses, respectively) were not. Baseline performance was characterized by a signal length dependent ability of the animals to discriminate between signal and non-signal events. Administration of nicotine (0.19, 0.62, 1.9 mumol) or of two novel nicotinic receptor agonists, ABT-418 and A-82695, did not produce main effects on vigilance performance. Lobeline (1.9, 6.2, 19 mumol), a nicotinic receptor ligand with mixed agonist/antagonist activities, impaired the animals' ability to discriminate between signal and non-signal events. The antagonist mecamylamine (5, 15, 50 mumol) potently impaired performance while increasing the number of errors of omission. The lack of effect of nicotine largely corresponds with the findings from previous studies on the acute effects of nicotine in intact subjects and non-smoking humans. While the detrimental effects of lobeline may have been related to the antagonist effects of this compound, the reasons for the differences between the effects of nicotine and lobeline still remain unsettled. These data support the hypothesis that nicotine receptor mechanisms are maximally activated in intact animals performing this task, and suggest that effects of acute nicotinic agonist treatment would not produce further cognitive benefit for these animals.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617808     DOI: 10.1007/BF02245840

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  59 in total

1.  Effects of systemic and intracerebroventricular administration of mecamylamine, a nicotinic cholinergic antagonist, on spatial memory in rats.

Authors:  M W Decker; M J Majchrzak
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Dynamic vs static stimuli in their effect on visual vigilance performance.

Authors:  H S Koelega; J A Brinkman; B Zwep; M N Verbaten
Journal:  Percept Mot Skills       Date:  1990-06

3.  Interaction of signal discriminability and task type in vigilance decrement.

Authors:  R Parasuraman; M Mouloua
Journal:  Percept Psychophys       Date:  1987-01

4.  Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline.

Authors:  C Reavill; B Walther; I P Stolerman; B Testa
Journal:  Neuropharmacology       Date:  1990-07       Impact factor: 5.250

5.  Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron.

Authors:  J L Muir; B J Everitt; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

6.  The effects of nicotine upon memory and problem solving performance.

Authors:  M P Dunne; D Macdonald; L R Hartley
Journal:  Physiol Behav       Date:  1986

7.  Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys.

Authors:  A V Terry; J J Buccafusco; W J Jackson
Journal:  Pharmacol Biochem Behav       Date:  1993-08       Impact factor: 3.533

8.  AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function.

Authors:  J L Muir; B J Everitt; T W Robbins
Journal:  J Neurosci       Date:  1994-04       Impact factor: 6.167

9.  Effects of central nicotinic cholinergic receptor blockade produced by chlorisondamine on learning and memory performance in rats.

Authors:  M W Decker; M J Majchrzak
Journal:  Behav Neural Biol       Date:  1993-09

10.  Behavioral vigilance in rats: task validation and effects of age, amphetamine, and benzodiazepine receptor ligands.

Authors:  J McGaughy; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

View more
  23 in total

1.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.

Authors:  Amir H Rezvani; Marty Cauley; Hannah Sexton; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 2.  CNTRICS final animal model task selection: control of attention.

Authors:  C Lustig; R Kozak; M Sarter; J W Young; T W Robbins
Journal:  Neurosci Biobehav Rev       Date:  2012-06-06       Impact factor: 8.989

3.  Strain dependency of the effects of nicotine and mecamylamine in a rat model of attention.

Authors:  Britta Hahn; Katelyn E Riegger; Greg I Elmer
Journal:  Psychopharmacology (Berl)       Date:  2016-02-15       Impact factor: 4.530

Review 4.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

Review 5.  Modulators in concert for cognition: modulator interactions in the prefrontal cortex.

Authors:  Lisa A Briand; Howard Gritton; William M Howe; Damon A Young; Martin Sarter
Journal:  Prog Neurobiol       Date:  2007-06-30       Impact factor: 11.685

Review 6.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

7.  Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex.

Authors:  Lori A Newman; Jenna Darling; Jill McGaughy
Journal:  Psychopharmacology (Berl)       Date:  2008-06-22       Impact factor: 4.530

8.  Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test.

Authors:  Jared W Young; Jessica M Meves; Mark A Geyer
Journal:  Behav Brain Res       Date:  2012-11-29       Impact factor: 3.332

Review 9.  nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms.

Authors:  Martin Sarter; Vinay Parikh; William M Howe
Journal:  Biochem Pharmacol       Date:  2009-05-04       Impact factor: 5.858

10.  Cognitive control deficits during mecamylamine-precipitated withdrawal in mice: Possible links to frontostriatal BDNF imbalance.

Authors:  Vinay Parikh; Robert D Cole; Purav J Patel; Rachel L Poole; Thomas J Gould
Journal:  Neurobiol Learn Mem       Date:  2016-01-13       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.